Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-06-20
2006-06-20
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S192100, C530S350000, C530S388200
Reexamination Certificate
active
07063847
ABSTRACT:
Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.
REFERENCES:
patent: 5262303 (1993-11-01), Sipe et al.
patent: 5506120 (1996-04-01), Yamamoto et al.
patent: 5696230 (1997-12-01), Sanderson
patent: 5827666 (1998-10-01), Finn et al.
patent: 5955073 (1999-09-01), Rybak et al.
patent: 5976546 (1999-11-01), Laus et al.
patent: 5989552 (1999-11-01), McKenzie et al.
patent: 6146631 (2000-11-01), Better et al.
patent: 6248352 (2001-06-01), Romet-Lemonne et al.
patent: 0 145 174 (1985-06-01), None
patent: 2 117 514 (1983-10-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 92/11031 (1992-07-01), None
patent: WO 93/10814 (1993-06-01), None
patent: WO 95/25957 (1995-09-01), None
patent: WO 96/22377 (1996-07-01), None
Buchner, R., et al.,Characterization of Site-Directed Neutralizing Antibodies Specific for a PeptidekR(33)Derived from the Predicted Amino Terminal Region of the HumankReceptor, The American Association of Immunologists, 1997, pp. 0022-1767.
Dempsey, P., et al.,C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity, Science, vol. 271, Jan. 1996, pp. 348-350.
Ember, J., et al.,Biologic Activity of Synthetic Analogues of C5a Anaphylatoxin, The Journal of Immunology, vol. 148, No. 10, May 15, 1992, pp. 3165-3173.
Goodman, M., et al.,Potentiation of the Primary Humoral Immune Response in Vitro By C5a Anaphylatoxin, The Journal of Immunology, vol. 129, No. 1, Jul. 1982, pp. 70-75.
Hobbs, M., et al.,Induction of Human B Cell Differentiation by Fc Region Activators, Clinical Immunology and Immunopathology, vol. 50, 1989, pp. 251-263.
Morgan, E.,Regulaton of Human B Lymphocyte Activation by Opoid Peptide Hormones Inhibition of IgG Production by Opioid Receptor Class(μ-, κ-, δ-)Selective Agonists, Journal of Neuroimmunology, vol. 65, 1 1996, p. 21-30.
Morgan, E., et al.,Characterization of Neutralizing Antibodies Specific for a Peptide, C5aR-(9-29) ,Derived from the Predicted Amino-Terminal Sequence of the Human C5a Receptor, The Journal of Immunology, vol. 151, No. 1, Jul. 1, 1993, pp. 377-388.
Rammensee, H-G., et al.,Peptides Naturally Presented by MHC Class I Molecules, Annu. Rev. Immunol., vol. 11, 1993, pp. 213-244.
Sanderson, S., et al.,Decapeptide Agonists of Human C5a: The Relationship between Conformation and Spasmogenic and Platelet Aggregatory Activities, Journal of Medicinal Chemistry, vol. 37, No. 19, 1994, pp. 3171-3180.
Tempero, R., et al.,Molecular Adjuvant Effects of a Conformationally Biased Agonist of Human C5a Anaphylatoxin, The Journal of Immunology, 1997, pp. 1377-1382.
Barclay et al., “GM-CSFR, Granulocyte-Macrophage Colongy-Stimulating Factor Receptor.” The Leucocyte Antigen Facts Book, 1997, Second Edition, Academic Press, London.
Guyre et al., “Monoclonal Antiboides that Bind to Distinct Epitopes on FcγRI are Able to Trigger Receptor Function.” The Journal of Immunoogy, 1989, pp. 1650-1655, vol. 143, No. 5.
Kennedy et al., “Protein-Protein Coupling Reactions and the Applications of Protein Conjugates.” Clinica Chimica Acta, 1976, pp. 1-31, vol. 70.
Baier, G. et al. “Immunogenic Targeting of Recombinant Peptide Vaccines to Human Antigen-Presenting Cells by Chimeric Anti-HLA-DR and Anti-Surface Immonoglobulin D Antibody Fab Fragments In Vitro”; Journal of Virology, 69(4): 2357-2365 (1995).
Ember, J.A. et al. “Biologic Activity of Synthetic Analogues of C5a Anaphylatoxin”; Journal of Immunology, 148; 3165-3173 (1992).
Sanderson, S.D. et al. “Decapeptide Agonists of Human C5a: The Relationship between Conformation and Spasmogenic and Platelet Aggregatory Activities”; J. Med. Chem., 37: 3171-3180 (1994).
Tempero, R.M. et al. “Molecular Adjuvant Effects of a Conformationally Biased Agonist of Human C5a Anaphylatoxin”; The Journal of Immunology, 158: 1377-1382 (1997).
Sanderson, S.D. et al. “Decapeptide Agonists of Human C5a: The Relationship between Conformation and Neutrophil Response”; J. Med. Chem., 38: 3669-3675 (1995).
Hollingworth Michael A.
Sanderson Sam D.
Tempero Richard M.
Dann Dorfman Herrell and Skillman
Ewoldt G. R.
Netter, Jr. Robert C.
Rigaut Kathleen D.
The Board of Regents of the University of Nebraska
LandOfFree
Compositions and methods for enhancing immune responses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhancing immune responses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhancing immune responses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3680575